-
Mashup Score: 13Optimizing preceding and consolidation therapies to prevent post-CAR-T relapse in B-ALL - 16 hour(s) ago
Valentin Ortiz-Maldonado, MD, Hospital Clinic Barcelona, Barcelona, Spain, discusses strategies for preventing relapse in patients with B-cell acute lymphoblastic leukemia (B-ALL) in both the pre and post-CAR-T setting. Dr Ortiz-Maldonado mentions an analysis being conducted by the GoCART Coalition to gain data on the impact of preceding and consolidation regimens, to identify the optimal sequencing of therapies, and to select patients for which these regimens will be the most effective. This interview took place at the 50th Annual Meeting of the EBMT in Glasgow, Scotland. These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
Source: www.vjhemonc.comCategories: General Medicine News, Onc News and JournalsTweet
-
Mashup Score: 4Novel targets & agents in myeloma - 18 hour(s) ago
In this discussion, Faith Davies, MD, MRCP, MRCPath, FRCPath, NYU Langone, New York City, NY, Mala Shanmugam, MS, PhD, Emory School of Medicine, Atlanta, GA, and Sikander Ailawadhi, MD, Mayo Clinic, Jacksonville, FL, give an overview of a session held at this year’s meeting which focused on novel targets and agents in myeloma. The experts cover a variety of exciting therapeutic strategies, including combination approaches with CELMoDs, how to overcome venetoclax resistance, and Phase I trials evaluating novel platforms which may be used to deliver therapies to patients. This session was filmed at the 17th International Workshop on Multiple Myeloma (iwMyeloma) held in Miami, FL. These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
Source: www.vjhemonc.comCategories: General Medicine News, Onc News and JournalsTweet
-
Mashup Score: 0
Both inflammatory activation and dysregulation of the immune response in the bone marrow niche are key players in the pathogenesis of myelodysplastic syndromes (MDS). Manja Wobus, PhD, University Hospital Carl Gustav Carus, Dresden, Germany, discusses the findings of preclinical studies investigating tasquinimod, a small molecular oral inhibitor of S100A9, for mitigating the effects of the pathological inflammasome activation in the bone microenvironment seen in MDS. The agent was studied in vitro in mesenchymal stromal cells (MSCs) and in vivo in transgenic murine models. Dr Wobus highlights that the findings provide the first evidence that tasquinimod may have potential benefits for cytopenic patients with lower-risk MDS. This interview took place at the European School of Hematology 9th Translational Research Conference on Myelodysplastic Syndromes (ESH MDS) in Budapest, Hungary. These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treat
Source: www.vjhemonc.comCategories: General Medicine News, Onc News and JournalsTweet
-
Mashup Score: 15
Arjun Ghosh, MBBS, MSc, PhD, FHEA, FACC, FESC, FRCP, FICOS, University College London Hospitals, London, UK, discusses cardiotoxicity following CAR T-cell therapy, an emerging area of concern for both hematologists and cardiologists as the scope of the indications for this therapeutic option widens. A significant proportion of patients are at risk of developing cardiotoxicity; however, with increasing real-world data, the understanding of how to manage these patients is improving. Dr Ghosh highlights the efficacy of tocilizumab treatment as prophylaxis for both cytokine release syndrome (CRS) and cardiotoxicity following CAR-T. This interview took place at the 64th Annual Scientific Meeting of the British Society for Haematology (BSH) Congress in Liverpool, UK. These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
Source: www.vjhemonc.comCategories: General Medicine News, Onc News and JournalsTweet
-
Mashup Score: 1iwMyeloma 2024 Session I: approaching bone disease, clinical trial updates & the value of MRD as an endpoint in trials - 2 day(s) ago
Tune in to this VJHemOnc podcast to hear experts Ola Landgren, Suzanne Lentzsch, Suzanne Trudel and Thomas Martin discuss updates with various agents in myeloma.
Source: www.vjhemonc.comCategories: General Medicine News, Onc News and JournalsTweet
-
Mashup Score: 3Developing patient-specific MRD markers for predicting and preventing MDS relapse post-SCT - 3 day(s) ago
Eva Hellström-Lindberg, MD, PhD, Karolinska University Hospital Huddinge, Stockholm, Sweden, discusses research into the development of measurable residual disease (MRD) markers using next-generation sequencing (NGS) and droplet digital polymerase chain reaction (ddPCR) to enable pre-emptive treatment and reduce relapse rates following stem cell transplantation (SCT) in patients with myelodysplastic syndromes (MDS) (NCT02872662). Despite initial assumptions that MRD markers could not be designed for MDS due to a lack of hotspot mutations, NGS and ddPCR were successfully employed to develop patient-specific MRD markers within four weeks of sampling. Using this methodology, patients who were found to be MRD-positive had a higher likelihood of subsequent relapse, and MRD-positivity was associated with routine therapeutic measures, such as donor lymphocyte infusion (DLI) or azacitidine treatment. Prof. Hellström-Lindberg highlights a novel prospective clinical trial that employs this metho
Source: www.vjhemonc.comCategories: General Medicine News, Onc News and JournalsTweet
-
Mashup Score: 2
In this discussion chaired by Francesco Maura, MD, Sylvester Comprehensive Cancer Center, University of Miami, Miami, FL, Charlotte Pawlyn, BA, MBBChir, MRCP, PhD, FRCPath, The Institute of Cancer Research, London, UK, Leif Bergsagel, MD, Mayo Clinic, Phoenix, AZ, and Paola Neri, MD, PhD, University of Calgary, Calgary, Canada, discuss mechanisms of resistance to various targeted therapies in multiple myeloma, including T-cell engagers and IMiDs. The experts highlight ongoing research in this space, and further explain how the immune microenvironment and cell intrinsic processes contribute to the development of resistance. To conclude, the experts discuss the value of exploring novel agents and combinations to improve outcomes for patients. This session was filmed at the 17th International Workshop on Multiple Myeloma (iwMyeloma) held in Miami, FL. These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights ar
Source: www.vjhemonc.comCategories: General Medicine News, Onc News and JournalsTweet
-
Mashup Score: 6
Dima El-Sharkawi, MBBS, MA, PhD, MRCP, FRCPath, The Royal Marsden NHS Foundation Trust, London, UK, briefly summarizes the current treatment landscape for patients with T-cell prolymphocytic leukemia (T-PLL). T-PLL is an extremely rare, aggressive mature T-cell leukemia and clinical outcomes remain poor for patients with the malignancy despite improvements in the understanding of the disease pathophysiology over the past two decades. While the standard treatment option continues to be alemtuzumab, Dr El-Sharkawi expresses optimism that novel drugs for T-PLL will be developed in the future. This interview took place at the 64th Annual Scientific Meeting of the British Society for Haematology (BSH) Congress in Liverpool, UK. These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
Source: www.vjhemonc.comCategories: General Medicine News, Onc News and JournalsTweet
-
Mashup Score: 3
Mary Frances McMullin, MD, Queen’s University, Belfast, UK, provides insight into managing moderate to severe anemia in patients with myelofibrosis (MF). It is crucial that clinicians investigate the cause of the anemia and measure erythropoietin levels prior to initiating treatment. The anemia can then be managed with erythropoiesis-stimulating agents (ESAs) or several other agents, such as danazol. Prof. McMullin also emphasizes that ruxolitinib, the frontline treatment option for MF, may decrease hemoglobin levels and worsen anemia; therefore, the novel agent momelotinib will likely become the first choice when treating patients. This interview took place at the 64th Annual Scientific Meeting of the British Society for Haematology (BSH) Congress in Liverpool, UK. These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
Source: www.vjhemonc.comCategories: General Medicine News, Onc News and JournalsTweet
-
Mashup Score: 12Post-ASCO & EHA 2024 Highlights - 4 day(s) ago
Webinar series by VJHemOnc featuring presentations & discussions on key abstracts in hematological malignancies presented at the ASCO & EHA 2024 meetings.
Source: www.vjhemonc.comCategories: General Medicine News, Onc News and JournalsTweet-
Join us for our Post-ASCO & EHA 2024 Highlights 📣 🩸 Featuring presentations & panel discussions on selected abstracts from #ASCO & #EHA 2024 🔦 REGISTER 👉 https://t.co/K156Bqw85Z #EHA2024 #ASCO24 @harrisoncn1 @myelomaMD @Daver_Leukemia @AnnaSureda5 @DrMDavids @Dr_AmerZeidan https://t.co/5RxaWFSHs4
-
#EBMT2024 | @ValentinOrtizMD (@hospitalclinic) speaks on optimizing preceding and consolidation therapies to prevent post #CART relapse in patients with B-ALL. Click here to watch: 👉 https://t.co/FeLISBCnAo #Leusm #ALLsm #Leukemia #ImmunoOnc #CARTCell #HemOnc @TheEBMT